Sherman Holtan, MD
Masonic Cancer Center, University of Minnesota
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sherman Holtan, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:10 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05123040 · Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated CorticosteroidsMasonic Cancer Center, University of Minnesota · terminated · Acute-graft-versus-host Disease · principal investigator
- Ph1/Ph2NCT05120570 · PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC TransplantationMasonic Cancer Center, University of Minnesota · completed · Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.